In recent years, biotech has claimed an increasing share of novel treatments approved by the US Food and Drug Administration; that trend will shift this year. Although recombinant drugs account for more than one-third of candidates in discovery, the share dwindles along the pipeline. Currently, only 8 out of 100 new drug or biologic applications are for biotech treatments. Only eight biotech drugs on the market have sales over $1 billion, but analysts suggest several late-stage products could turn into blockbusters.
Credit: Source: BioPharm Insight
Credit: Source: BioPharm Insight
Credit: Source: Food and Drug Administration, Center for Biologics Evaluation and Research
Credit: Source: SG Cowen
Credit: Source: IMS Health, Credit Suisse First Boston
Rights and permissions
About this article
Cite this article
Lawrence, S. The biotech drug market. Nat Biotechnol 22, 1496 (2004). https://doi.org/10.1038/nbt1204-1496
Issue Date:
DOI: https://doi.org/10.1038/nbt1204-1496
